2023 - Research.com Medicine in Netherlands Leader Award
Eric P. Krenning mainly investigates Internal medicine, Somatostatin, Endocrinology, Octreotide and Radionuclide therapy. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Oncology. His studies deal with areas such as Receptor, Cancer research, Pancreas and Pathology as well as Somatostatin.
His study in Endocrinology is interdisciplinary in nature, drawing from both Pharmacokinetics, Arginine, El Niño and Biodistribution. His Octreotide study combines topics in areas such as Radiation therapy, Nuclear medicine, Chemotherapy and Renal function. Eric P. Krenning combines subjects such as Peptide receptor, Clinical trial and Toxicity with his study of Radionuclide therapy.
His main research concerns Internal medicine, Endocrinology, Somatostatin, Radionuclide therapy and Octreotide. The various areas that he examines in his Internal medicine study include Gastroenterology and Oncology. His Endocrinology study incorporates themes from Peptide and Biodistribution.
His work deals with themes such as Cancer research, Kidney and Pharmacology, which intersect with Somatostatin. His Radionuclide therapy study combines topics from a wide range of disciplines, such as Peptide receptor, Octreotate, DOTA and Toxicity. His work focuses on many connections between Octreotide and other disciplines, such as Scintigraphy, that overlap with his field of interest in Pathology.
His scientific interests lie mostly in Internal medicine, Neuroendocrine tumors, Radionuclide therapy, Oncology and Gastroenterology. His Internal medicine research is multidisciplinary, incorporating elements of Endocrinology and Pathology. His research integrates issues of Clinical endpoint, Quality of life, Surgery and 177Lu-DOTATATE in his study of Neuroendocrine tumors.
His Radionuclide therapy research is multidisciplinary, incorporating perspectives in Cancer research, Peptide receptor, Chromogranin A and Somatostatin receptor, Somatostatin. His Gastroenterology study integrates concerns from other disciplines, such as Octreotate and Pancreatectomy. His study explores the link between Octreotide and topics such as Chemotherapy that cross with problems in Adverse effect.
His primary areas of study are Internal medicine, Neuroendocrine tumors, Radionuclide therapy, Pathology and Endocrinology. His research in Internal medicine intersects with topics in Gastroenterology and Oncology. His Neuroendocrine tumors research integrates issues from Radiology and Somatostatin receptor.
His Radionuclide therapy research includes elements of Peptide receptor, Randomized controlled trial, Octreotide, Somatostatin and Toxicity. In his research, Adverse effect is intimately related to Cancer, which falls under the overarching field of Somatostatin. He has included themes like Appendiceal neoplasms and MEDLINE in his Endocrinology study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg;G. El-Haddad;Edward Wolin;A. Hendifar.
The New England Journal of Medicine (2017)
Gastroenteropancreatic neuroendocrine tumours.
Irvin M Modlin;Kjell Oberg;Daniel C Chung;Robert T Jensen.
Lancet Oncology (2008)
Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
Dik J. Kwekkeboom;Wouter W. de Herder;Boen L. Kam;Casper H. van Eijck.
Journal of Clinical Oncology (2008)
The role of somatostatin and its analogs in the diagnosis and treatment of tumors.
Steven W. J. Lamberts;Eric P. Krenning;Jean-Claude Reubi.
Endocrine Reviews (1991)
ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.
Marianne Pavel;Eric Baudin;Anne Couvelard;Eric Krenning.
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
M. Pavel;D. O''Toole;F. Costa;J. Capdevila.
LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN
E.P. Krenning;W.A.P. Breeman;P.P.M. Kooij;J.S. Lameris.
The Lancet (1989)
Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
Dik J. Kwekkeboom;Jaap J. Teunissen;Willem H. Bakker;Peter P. Kooij.
Journal of Clinical Oncology (2005)
Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity
Annemieke M. Boot;Maria A. J. de Ridder;Huibert A. P. Pols;Eric P. Krenning.
The Journal of Clinical Endocrinology and Metabolism (1997)
[177Lu-DOTA0, Tyr3]octreotate : comparison with [111In-DTPA0]octreotide in patients
Dik J. Kwekkeboom;Willem H. Bakker;Peter P. M. Kooij;Mark W. Konijnenberg.
European Journal of Nuclear Medicine and Molecular Imaging (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: